Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
Andrea
A
De Luca
Katleen
K
de Gaetano Donati
Alessandro
A
Cozzi-Lepri
Manuela
M
Colafigli
Amalia
A
De Curtis
Maria Rosaria
MR
Capobianchi
Andrea
A
Antinori
Andrea
A
Giacometti
Giacomo
G
Magnani
Vincenzo
V
Vullo
Roberto
R
Cauda
Licia
L
Iacoviello
Antonella
A
d'Arminio Monforte
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008137:Longitudinal Studies; D012307:Risk Factors; D013997:Time Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood; D000099227:Abacavir
D019380:Anti-HIV Agents; D015415:Biomarkers; D002097:C-Reactive Protein; D015224:Dideoxynucleosides; D005338:Fibrin Fibrinogen Degradation Products; D015850:Interleukin-6; D019010:Vascular Cell Adhesion Molecule-1; D000099227:Abacavir; C508600:IL6 protein, human; C036309:fibrin fragment D